Novavax Starts Dosing In COVID-19 Booster Trial In Participants Aged 12 - 17 Years

  • Novavax Inc NVAX has initiated the administration of the first booster doses of NVX-CoV2373 in the pediatric expansion of the PREVENT-19 pivotal Phase 3 trial. 
  • The study will evaluate the safety and immunogenicity of a third dose of NVX-CoV2373 among trial participants aged 12 through 17.
  • All PREVENT-19 trial participants aged 12 through 17 are now eligible to receive a third booster dose of NVX-CoV2373. 
  • Related: Novavax's COVID-19/Influenza Combo Vaccine Shows Immunogenicity In Early-Study.
  • The booster dose is identical to the active vaccine previously administered to the participants in a two-dose regimen (5 micrograms of recombinant spike protein plus 50 micrograms of Matrix-M adjuvant).
  • It can be administered at least five months after receiving the active vaccine. 
  • Post-booster objectives include the assessment of the humoral immune response 28 days after the administration of the booster dose, as well as describing COVID-19 disease. 
  • Also See: Novavax's COVID-19 Vaccine Scores Green Light In India with First Approval For Adolescents
  • Initial results are expected during 2H of 2022.
  • Price Action: NVAX shares closed at $48.90 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!